Revvity: Business Model, SWOT Analysis, and Competitors 2026

Revvity, Inc. stands as a leading company in Healthcare. Generating $2.86 billion in annual revenue (growing 5.9% year-over-year) and carrying a market capitalization of $10.95 billion, the company has cemented its position as a foundational player in the global Diagnostics & Research landscape. Under the leadership of its leadership team, Revvity, Inc. continues to execute on a multi-year strategic vision that balances growth investment with shareholder returns.

This in-depth analysis examines Revvity, Inc.'s business model, financial performance, competitive positioning, and SWOT analysis as of 2026. Whether you're evaluating Revvity, Inc. as an investment, benchmarking it against peers, or researching its strategy, this guide covers the key factors that define Revvity, Inc.'s position in the Diagnostics & Research market today.

What You Will Learn

1. How Revvity, Inc. generates revenue across its key business segments and the unit economics behind each
2. A data-backed SWOT analysis covering Revvity, Inc.'s competitive strengths, operational weaknesses, market opportunities, and external threats
3. Who Revvity, Inc.'s main competitors are and how the company compares on key financial metrics
4. Revvity, Inc.'s key financial metrics: revenue, profit margins, market cap, free cash flow, and valuation multiples
5. Revvity, Inc.'s strategic direction and what to watch in 2026-2027

Key Takeaways

• Revenue: $2.86 billion annual revenue (TTM), +5.9% YoY
• Market Cap: $10.95 billion — one of the largest companies in the Healthcare sector
• Profitability: Gross margin 54.8%, operating margin 20.1%, net margin 8.4%
• Free Cash Flow: $523.28 million
• Return on Equity: 3.2% — reflects current investment phase
• Employees: 11,000 worldwide

Who Owns Revvity, Inc.?

Revvity, Inc. is publicly traded on the NYQ under the ticker symbol RVTY. As a public company, it is owned by millions of shareholders ranging from retail investors to major institutional holders.

The largest shareholders of Revvity, Inc. are typically major institutional investors including The Vanguard Group, BlackRock, and State Street Corporation — which collectively often hold 15-25% of publicly traded US companies. Insider ownership and the concentration of voting rights vary; investors should review the latest proxy statement filed with the SEC for precise ownership data.

Revvity, Inc. has approximately 0.11 billion shares outstanding, with float shares of 0.00 billion — the freely tradeable portion. The stock trades at $96.57 per share as of early 2026.

Revvity, Inc.'s Mission Statement

Revvity, Inc.'s strategic mission is aligned with its core business activities in the Diagnostics & Research sector. The company's stated values and mission inform its capital allocation decisions, talent strategy, and long-term product roadmap. Mission statements for public companies are disclosed in annual reports and investor presentations — Revvity, Inc.'s most recent proxy statement and annual report are the authoritative sources for its current mission and values.

A company's mission statement matters because it signals strategic intent to employees, investors, and customers. For Revvity, Inc., the mission encompasses not just what the company does, but why it exists and how it creates value for stakeholders. Companies that maintain alignment between their stated mission and actual capital allocation decisions tend to build stronger brand trust and employee engagement over time.

In practice, Revvity, Inc.'s strategic priorities as communicated to investors in 2025-2026 center on revenue growth and market share expansion, profitability improvement, and sustainable returns of capital to shareholders. These operational priorities translate directly into the business model and investment thesis discussed in the following sections.

How Does Revvity, Inc. Make Money?

Revvity, Inc. provides health sciences solutions, technologies, and services. The company offers instruments, reagents, software, subscriptions, detection and imaging technologies, extended warranties, training and services; and instruments, reagents, assay platforms and software products for early detection of common and rare conditions, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. The company also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for

Revvity, Inc.'s business model is built around delivering value to its customers in the Diagnostics & Research segment of the Healthcare sector. The company generates revenue through its core product and service offerings, leveraging its market position, operational capabilities, and customer relationships to sustain competitive advantage. Like most companies in Diagnostics & Research, Revvity, Inc.'s financial performance is influenced by industry-wide pricing dynamics, input costs, and the balance between volume growth and margin management.

Management's strategic priorities — as disclosed in investor communications — focus on sustainable revenue growth, disciplined capital allocation, and building long-term shareholder value. Investors should review Revvity, Inc.'s latest annual report (10-K or equivalent) and quarterly earnings releases for the most current financial disclosures and strategic updates.

Revvity, Inc. Business Model Canvas

The Business Model Canvas framework provides a structured view of how Revvity, Inc. creates, delivers, and captures value.

Key Partners: Revvity, Inc.'s key partners include suppliers, distributors, technology providers, and strategic alliances that enable its core operations. In the Diagnostics & Research sector, these relationships provide supply chain resilience, expanded distribution, and access to complementary capabilities.

Key Activities: Revvity, Inc.'s most important activities center on product development and innovation, sales and marketing, supply chain management, customer service, and regulatory compliance. The company's ability to execute these activities at scale is a core competency.

Key Resources: Revvity, Inc.'s critical resources include its brand equity, intellectual property portfolio, customer relationships, human capital (11,000 employees), proprietary technology, and financial resources ($919.86M in cash).

Value Propositions: Revvity, Inc. delivers value to customers through product quality, brand trust, convenience, innovation, and price competitiveness. The specific value proposition varies by customer segment but consistently addresses core needs in the Diagnostics & Research market.

Customer Relationships: Revvity, Inc. maintains customer relationships through multiple channels including direct sales teams, digital platforms, customer service centers, and loyalty/membership programs. Customer retention is a key operational priority.

Channels: Revvity, Inc. reaches customers through its own direct channels (stores, website, apps), third-party retailers and distributors, and partner networks. The mix of direct vs. indirect channels affects margin structure and customer data ownership.

Customer Segments: Revvity, Inc. serves multiple distinct customer segments, which may include consumers, small and medium businesses, enterprise clients, and government entities — depending on its product portfolio and market positioning.

Cost Structure: Revvity, Inc.'s major costs include cost of goods sold (45.2% of revenue), research & development, sales & marketing, general & administrative expenses, and capital expenditures. Total operating costs represent 79.9% of revenue.

Revenue Streams: Revvity, Inc. generates revenue through its core product and service offerings.

Revvity, Inc. Competitors

Revvity, Inc. competes against Johnson & Johnson (JNJ), UnitedHealth Group (UNH), Pfizer (PFE), AbbVie (ABBV), Eli Lilly (LLY) and others in the Diagnostics & Research segment of the Healthcare sector.

Revvity, Inc. SWOT Analysis

A SWOT analysis examines Revvity, Inc.'s internal strengths and weaknesses alongside external opportunities and threats.

Strengths

• Strong Margins: Revvity, Inc.'s gross margin of 54.8% is well above industry averages, reflecting pricing power, operational efficiency, or a high-value product mix. The operating margin of 20.1% demonstrates disciplined cost management even at scale.

Weaknesses

• Competitive Scale Pressure: In the Diagnostics & Research sector, larger competitors with greater economies of scale can exert pricing pressure and outspend Revvity, Inc. on marketing, R&D, and distribution — limiting the company's ability to defend market share in a price-sensitive environment.
• Market Concentration Risk: Revenue concentration in core markets or customer segments creates vulnerability to localized downturns, regulatory changes, or shifts in customer preferences. Diversification remains an ongoing strategic challenge.

Opportunities

• Total Addressable Market: Revvity, Inc. operates in the Diagnostics & Research segment of the broader Healthcare sector, which represents a $12 trillion global healthcare market by 2030. Even modest share gains in this environment translate to meaningful revenue upside, particularly as the company expands its product portfolio and geographic reach.
• International Expansion: Emerging markets — particularly India (1.4B people, rapidly growing middle class), Southeast Asia (700M people), and Sub-Saharan Africa — represent significant untapped addressable markets for Revvity, Inc.'s products and services.
• Strategic Acquisitions: With $919.86M in cash and strong free cash flow generation, Revvity, Inc. is well-positioned to pursue strategic acquisitions that expand its capabilities, customer base, or geographic reach.

Threats

• Macroeconomic Sensitivity: Global economic slowdowns, inflation, or rising interest rates can reduce consumer and enterprise spending. Revvity, Inc.'s revenue is not fully insulated from macroeconomic cycles, and a recession scenario could meaningfully impact demand.
• Regulatory and Geopolitical Risk: Increasing government regulation — particularly data privacy laws (GDPR, CCPA), antitrust enforcement, and trade restrictions — poses compliance costs and potential restrictions on Revvity, Inc.'s business model across key markets.
• Talent Competition: Competition for skilled technology, engineering, and management talent remains intense. High employee turnover or inability to attract top talent could slow innovation and execution — particularly critical in an era of AI-driven competition.

AI Margin Pressure Analysis

PitchGrade has published a dedicated analysis of how artificial intelligence is reshaping Revvity's competitive position, margins, and long-term outlook.

Read the full AI Margin Pressure analysis →

Conclusion

Revvity, Inc. enters 2026 as a leading company in Healthcare, backed by $2.86 billion in annual revenue and a 8.4% net profit margin. The company's 54.8% gross margins and $523.28 million in free cash flow provide the financial foundation to fund growth initiatives while returning capital to shareholders.

The primary opportunities ahead lie in expanding market share, operational efficiency improvements, and selective geographic expansion. The key risks to monitor include competitive pressure from established peers and new entrants, macroeconomic headwinds, and regulatory developments in Revvity, Inc.'s core markets.

For investors, Revvity, Inc.'s 46.9x trailing P/E and 16.1x forward P/E reflect the market's expectations for stable earnings. Analysts and investors should watch quarterly earnings releases, management commentary on comparable sales growth, margin trends, and capital allocation for signals of how the investment thesis is progressing.

Data Sources

Financial data and business information for this analysis was sourced from: Yahoo Finance – Revvity, SEC EDGAR – Revvity Filings, and Revvity's investor relations materials.

All financial figures reflect the most recent publicly available disclosures. Investors should verify current data before making investment decisions.

Frequently Asked Questions

1. 1. What is Revvity's primary revenue stream?

Revvity, Inc. generates $2.86 billion in annual revenue (TTM) with a 54.8% gross margin, growing 5.9% year-over-year. The company's revenue model is described in detail in the business model section above.

2. 2. What are Revvity's strengths?

Revvity, Inc.'s core strengths include: Revvity, Inc.'s gross margin of 54.8% is well above industry averages, reflecting pricing power, operational efficiency, or a high-value product mix. The operating margin of 20.1% demonstrates discipl These advantages contribute to the company's durable competitive position in the Diagnostics & Research sector.

3. 3. Who are Revvity's main competitors?

Revvity, Inc. competes in the Diagnostics & Research segment of the Healthcare sector. The competitor comparison table in this article outlines key peers by market cap, revenue, and margins. Competitive dynamics in Diagnostics & Research center on product differentiation, pricing strategy, and distribution scale.

4. 4. What opportunities exist for Revvity?

Revvity, Inc.'s key growth opportunities include: Revvity, Inc. operates in the Diagnostics & Research segment of the broader Healthcare sector, which represents a $12 trillion global healthcare market by 2030. Even modest share gains in this environ Emerging markets — particularly India (1.4B people, rapidly growing middle class), Southeast Asia (700M people), and Sub-Saharan Africa — represent significant untapped addressable markets for Revvity With $919.86M in cash and strong free cash flow generation, Revvity, Inc. is well-positioned to pursue strategic acquisitions that expand its capabilities, customer base, or geographic reach.

5. 5. What threats does Revvity face?

Revvity, Inc. faces the following external threats: Global economic slowdowns, inflation, or rising interest rates can reduce consumer and enterprise spending. Revvity, Inc.'s revenue is not fully insulated from macroeconomic cycles, and a recession sc Increasing government regulation — particularly data privacy laws (GDPR, CCPA), antitrust enforcement, and trade restrictions — poses compliance costs and potential restrictions on Revvity, Inc.'s bus Competition for skilled technology, engineering, and management talent remains intense. High employee turnover or inability to attract top talent could slow innovation and execution — particularly cri Monitoring these risks is essential for investors tracking the company's long-term trajectory.

6. 6. How does Revvity ensure customer satisfaction?

Revvity, Inc. generates $2.86 billion in annual revenue (TTM) with a 54.8% gross margin, growing 5.9% year-over-year. The company's revenue model is described in detail in the business model section above.

7. 7. What markets does Revvity target?

Revvity, Inc. generated $2.86 billion in annual revenue with a 8.4% net profit margin as of the latest reporting period. The company operates in the Diagnostics & Research sector. For the most current information, consult Revvity, Inc.'s investor relations page.

8. 8. How does Revvity differentiate itself from competitors?

Revvity, Inc. generates $2.86 billion in annual revenue (TTM) with a 54.8% gross margin, growing 5.9% year-over-year. The company's revenue model is described in detail in the business model section above.